EASME

Vital Beats is a developer of a medical platform focused on providing clinical decision support for the remote care of heart patients with pacemakers. The platform employs machine learning and participatory design principles, combined with advanced analytics, to continuously monitor cardiac devices. By utilizing a patent-pending technique, it triages patients effectively, allowing for timely interventions. This approach enhances the management of chronic conditions, ensuring that patients benefit from digital healthcare solutions that monitor their implanted devices around the clock. Vital Beats emphasizes user experience by integrating Nordic aesthetics into its platform, making it both enjoyable and valuable for users.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Enzymlogic specializes in enzymology and protein science, offering analytical services aimed at enhancing drug discovery and development for the pharmaceutical and biotech industries. The company assists in identifying kinetic profiles during the drug development process, which helps clinicians understand the interactions between drugs and their targets. This insight is crucial for evaluating factors that influence efficacy and safety, ultimately contributing to the creation of innovative therapies that improve patients' quality of life. Enzymlogic aims to become a key resource for organizations focused on successful drug discovery, ensuring their clients achieve optimal returns on investment while advancing therapeutic solutions.

Raylytic develops the only fully integrated platform for automated medical image analysis and clinical data extraction. They develop UNITY, the only fully integrated software platform that streamlines the setup and conduct of clinical data collection tasks, including CRFs, PROMs and AI-based medical image analysis. UNITY is utilized to operate private registries, to conduct clinical trials for regulatory approval, post-market surveillance and general medical data collection tasks, providing the basis for evidence based medicine and the backing of product claims with documented, traceable scientific substantiation. Their modular framework utilizes algorithms from industrial and medical image processing as well as sophisticated machine learning algorithms, allowing for the first time the highly automated data extraction and quantification of endpoints based on medical images. The most recent addition is their Clinical Data Module, which seamlessly integrates the electronic capture of patient reported outcome measures (PROMs) into the clinical routine.

Inflection Biosciences is an early stage, drug development company with a focus on developing innovative small molecule therapeutics that address major unmet needs in cancer. With bases in Dublin and London, the company is dedicated to identifying excellent early stage cancer research from academic institutes and companies around the world. Inflection Biosciences will use its expertise to progress the most promising programs through pre-clinical and early clinical stages, partnering with larger. pharma for later stage clinical development and commercialisation. The company’s founders, including CEO Darren Cunningham and Director of R&D Dr. Michael O’Neill, bring over 60 years of industry experience along with access to a global network of potential partners and service providers.

Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

TomoWave commercializes and produces innovative imaging modalities with applications in clinical medicine and preclinical research. Our proprietary technology “listens to the sound of light” to produce highly resolved images from the depth of tissues. The main targeted medical needs of TomoWave platform technology include detection and diagnostics of cancer, image guided interventions and monitoring the effectiveness of anticancer therapy and diagnostics imaging of vascular and blood related conditions. A pipeline of innovative optoacoustic and laser ultrasonic imaging technologies based on inventions made by the company founder, Dr. Alexander Oraevsky, pioneer of biomedical optoacoustics and recipient of multiple grants and awards for development of molecular imaging systems and applications. TomoWave Laboratories has the capability to generate intellectual property and develop its IP from idea to validated clinical prototypes and brings these technologies to the market place through regulatory certification.

FGen is a Swiss start-up company founded 2011 in Basel as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract reasearch organization we collaborate with partners from Biotech, Life Sciences, and Pharma in order to establish efficient bioprocesses and to develop new biopharmaceuticals.

BioMensio Ltd. is a biotechnology company based in Tampere, Finland, established in 2015. It specializes in developing smart multi-analyte handheld detection devices for bio-analytics, providing rapid and on-site detection of various biological targets from a small sample in a single step. The company's offerings include a novel miniaturized micro-array platform that supports the quick development of new bio-screening applications, which are applicable in areas such as saliva testing, food and milk safety, point-of-care diagnostics, and bio-security. BioMensio's technology enables the creation of label-free assays, allowing for the detection of multiple analytes without the need for labeling procedures. Additionally, its Diagnostics-as-a-Service (DXaaS) platform integrates a handheld reader, multianalyte fluid cartridges, and cloud-based analytics, facilitating easier access for original equipment manufacturers (OEM) to develop bio-analysis products and services.

CLOVER Bioanalytical Software is a bioinformatics company specialized in data processing for Bioanalytical Chemistry and Microbial ID and other clinical diagnostics applications using mass spectrometry. Formed by a group of Ph.D. graduates with a wide expertise in business and research, it brings a perfect match to develop cutting-edge software and statistical analysis projects in the biomedical field. They are specialized in mass spectrometry, its clinical applications and mass spectrometry imaging. But their expertise cover many more applications, like medical image processing, univariate and multivariate statistical analysis, and Big Data. They are truly customer-oriented, keeping in mind the goals of their clients and the scalability of the systems. They count with experts in biomedicine, chemistry and biotechnology that speak your own language and understands your needs.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

More than just a medical device, liberDi is an innovative all-in-one portable Digital Dialysis Clinic providing scalable, digital and safe, self-care anywhere. It provides an Intelligent Dialysis Assistant (IDA) and remote medical supervision, together creating the ultimate Digital Dialysis Clinic, allowing patients to choose Anywhere PD (Peritoneal Dialysis) as first modality. liberDi’s system is positioned to replace traditional full-service, in-clinic care with a self-care system suitable for many dialysis patients. Focused on patient care liberation and improved quality of life, liberDi allows many more people requiring dialysis to do so easily and comfortably from wherever they are, be that their home, office or on vacation. Founded in 2014 and supported by a team of world-renowned scientists, engineers and physicians, liberDi’s vision and mission have always been to find a way to free dialysis patients from the need to spend half their lives dialyzing in expensive dialysis clinics and centers. liberDi’s cutting-edge innovation is safe, patient friendly, and portable. In addition to liberating patients, it also enables clinics to optimize their economic model and improve the quality of their service while lowering costs; This creates the optimal, world’s first, 360° platform for Renal patients and caregivers alike.

Pila Pharma AB is a clinical stage biotech company based in Malmö, Sweden, focused on developing XEN-D0501, a potent and selective TRPV1 antagonist. This molecule is being investigated as a treatment for type 2 diabetes, obesity, and the rare and painful condition erythromelalgia. XEN-D0501 has undergone testing in approximately 300 subjects across phase 1 and 2 trials, demonstrating a favorable safety profile in both healthy volunteers and patients with various conditions, including type 2 diabetes. The compound has shown efficacy in improving glucose-stimulated insulin secretion in type 2 diabetics. Recent preclinical safety studies for XEN-D0501 have been completed without adverse effects, allowing the company to advance to clinical trials lasting up to three months. In July 2022, Pila Pharma received US Orphan Drug Designation for XEN-D0501 for its application in treating erythromelalgia.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Cellestia Biotech AG is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for cancer and immunological disorders. Founded in 2014 as a spin-off from the École Polytechnique Fédérale de Lausanne, the company is headquartered in Basel, Switzerland, with an additional location in Lausanne. Cellestia focuses on its lead compound, CB-103, which is a novel oral pan-NOTCH inhibitor targeting NOTCH-dependent leukemia, lymphoma, and solid tumors. The drug has successfully advanced to Phase 2 clinical trials for patients with multi-drug resistant cancers. In addition to CB-103, Cellestia is developing a pipeline of novel transcription factor inhibitors and NOTCH-specific biomarkers to enhance patient selection and treatment outcomes. The company's approach aims to control and modulate pathogenic gene expression through selective inhibition of transcription factors in the cell nucleus, contributing to integrated drug and personalized medicine development.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

Cyclomics is a Dutch startup focused on revolutionizing cancer care through its proprietary circulating tumor DNA (ctDNA) detection technology. This innovative approach aims to provide faster and more reliable diagnoses, particularly for monitoring cancer recurrence and treatment responses, addressing critical clinical needs that current imaging methods struggle to meet. Cyclomics has developed a diagnostic kit, CyclomicsSeq, which offers superior performance compared to traditional radiological and physical examinations. The initial application of this technology targets head and neck cancers, where effective monitoring of treatment response and recurrence is vital for improving patient survival rates. By enabling accurate measurements and timely interventions, Cyclomics seeks to significantly enhance cancer diagnostics and patient outcomes.

Pre Diagnostics is an innovative Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing pioneering and patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept is built upon the scientific premise that a disease evokes systemic responses in macrophages unique to that disease which can be accurately measured in the blood samples of patients. Pre Diagnostics aims to be a leader in the diagnosis of early Alzheimer’s disease and is thus focused on the development of IVD biomarker products that use well-established technologies and procedures.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

ChemoTech is a Scandinavian company based at Medicon Village in Lund, Sweden. The company’s founders have extensive experience of cancer treatment through surgical oncology and clinical development. The company is dedicated to using its unique patented know-how to develop innovation in cancer care through genuine research and clinical trials.

Scandion Oncology A/S is a biotechnology company based in Copenhagen, Denmark, focused on developing treatments for chemotherapy resistance in cancer patients. Founded in 2017, the company is advancing its lead product, SCO-101, which is currently undergoing Phase II clinical trials for breast and colorectal cancers. Additionally, it is working on SCO-201, a product in late pre-clinical development aimed at treating solid tumors. Scandion Oncology collaborates with the University of Copenhagen to co-develop SCO-301, a candidate designed to reverse drug resistance, and has partnered with Per Norlén to investigate the combined anti-tumor effects of mitazalimab and SCO-101 in resistant tumor models. The company's mission is to enhance treatment outcomes and quality of life for cancer patients who experience chemotherapy resistance, addressing a significant challenge in oncology where nearly half of patients do not respond to chemotherapy.

CSF-Dynamics is developing a new type of hydrocephalus shunt that overcomes the major issues of current shunts on the market. The shunt is currently undergoing clinical testing. CSF-Dynamics expects the shunt to be approved for clinical use by end of year 2021.

Mecwins specializes in developing advanced nanomechanical sensing technology to create sensitive immunoassays aimed at improving healthcare outcomes for individuals at risk for oncology, cardiovascular diseases, and infectious diseases. Their innovative platform combines nanomechanical sensing with plasmonic emission using a sandwich immunoassay approach, allowing for the production of ultrasensitive detection systems. This technology enables researchers to achieve enhanced sensitivity in disease detection, ultimately contributing to better diagnostics and treatment options in critical areas of healthcare.

Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

CyTuVax is a clinical stage vaccine company focused on developing innovative solutions to address significant medical needs. The company collaborates with leading European research institutions to advance its adjuvant technology, which enhances immune responses in both humoral and cellular aspects. This technology can be applied to both prophylactic vaccines targeting viral and bacterial pathogens and therapeutic vaccines for cancer treatment. By utilizing depot-attached cytokines as immune stimulators, CyTuVax's platform aims to improve the efficacy of standard vaccines, reduce the number of required injections, and ultimately place the patient at the center of its vaccine development efforts.

Animated Language Learning is a multinational developer of software based language solutions serving special needs children across the globe. Their revolutionary approach to paediatric language development is currently undergoing clinical trials in the United States and Europe with ground-breaking results. They are based in Galway City in the west of Ireland with offices in San Francisco, California; Jackson, Mississippi; and Tokyo, Japan. Their first commercial product is planned to launch in Q3 2012.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced tests for cancer assessment and personalized treatment. The company offers a range of products including ConfirmMDx, a prostate cancer testing solution that addresses false-negative biopsy concerns; SelectMDx, which helps guide repeat biopsies for prostate cancer; and AssureMDx, a noninvasive liquid biopsy test for bladder cancer that assists in decision-making for cystoscopy. Additionally, MDxHealth provides PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Founded in 2003 and headquartered in Irvine, California, MDxHealth operates additional offices in Herstal, Belgium, and Nijmegen, the Netherlands. The company generates revenue through clinical laboratory services and the out-licensing of its patented DNA methylation platform and biomarkers, serving markets in the United States and Europe.

Ahead Therapeutics is a biotech company focused on developing innovative treatments for various autoimmune disorders. Utilizing a proprietary technology centered on PS-liposomes that contain auto-autoantigens, the company aims to induce antigen-specific immune tolerance through a biomimetic process. This approach allows for the customization of encapsulated auto-antigens, targeting conditions such as Type 1 Diabetes, Multiple Sclerosis, and Celiac Disease. The technology is designed primarily as a reverse therapeutic vaccine, potentially offering permanent cures rather than just palliative care. Ahead Therapeutics' method boasts several advantages, including long-lasting effects, non-systemic immunosuppression, minimal toxicity, cost-effective production, and compatibility with other therapies. The effectiveness of this liposome-based platform has been validated in animal models, and preclinical non-regulatory assessments are underway for specific indications. The company plans to advance to preclinical regulatory stages and expand its treatment pipeline to address additional autoimmune conditions, recognizing the significant impact these diseases have on the global population and healthcare costs.

CRU network has been providing clinical research services to the pharmaceutical industry for over a decade and basic/academic research services since 2015. In the recent years next to the research activities many new healthcare services were initiated within the EU and in South-East Asia. CRU sites are located in Hungary, Ukraine, Germany, Vietnam and LAO PDR.

Dicronis strive to enhance the quality-of-life of patients with their innovative technology. The first product in their pipeline, Lymphit, measures patient’s lymphatic function in a safe, home-based and highly scalable manner. The initial indication of Lymphit is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies. By remotely monitoring the lymphatic function, the physician is enabled for the first time to perform an early diagnosis, before the swelling has occurred, and evaluate the best conservative treatment for the patient. This leads to a great improvement of the prognosis and quality of life of the patient and important savings for the healthcare system and society.

Filterlex Medical Ltd. is a medical device startup focused on the cardiovascular field, specifically developing an advanced embolic protection device aimed at reducing the risk of stroke and other complications during catheter-based structural heart procedures. The company's innovative device utilizes next-generation technology to address the limitations of existing products. It is designed to be securely positioned in the aorta, providing comprehensive embolic protection by deflecting, capturing, and removing embolic particles. This approach enables physicians to enhance patient safety during these complex procedures. Currently, Filterlex is seeking seed funding to further advance its development efforts.

RegStem is an early stage biopharmaceutical company repurposing molecules and creating new treatments in the fields of regenerative medicine and more specifically in the areas of rare muscle and blood diseases with high unmet medical needs.

IRLAB Therapeutics AB is a Swedish research and development company focused on creating innovative treatments for neurological disorders, particularly Parkinson’s disease. The company is advancing several drug candidates, including Mesdopetam, a dopamine D3 receptor antagonist, and IRL752, which targets postural dysfunction. Both compounds have successfully completed Phase IIa clinical trials. Additionally, IRLAB is exploring other research programs aimed at addressing neurodegenerative disorders and aging, such as IRL942, P001, and P003, which seeks alternatives to levodopa for Parkinson’s treatment. By focusing on the core dysfunctions associated with Parkinson’s disease and dementias, IRLAB aims to enhance the quality of life for patients suffering from these conditions. The company is headquartered in Gothenburg, Sweden.

Khondrion is a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, the company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.

Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

ATXA Therapeutics Limited is a spin-out company from University College Dublin whose primary focus is to advance clinical trials and to secure marketing authorization of novel therapies for the treatment of Pulmonary Arterial Hypertension (PAH), serving a previously unmet medical need by offering improved treatment options to the prescribing physician and new hope for the PAH patient. Founded by Professor Therese Kinsella, ATXA was incorporated in May 2015 and is the culmination of over 20 years of extensive research and over €15m of grant funding and a proven track record in understanding of the biology and signalling of the human prostanoid receptors in the cardiovascular disease and oncology setting. Supported with funding from a number of technology and commercialization development grants from Enterprise Ireland and Science Foundation Ireland, ATXA has developed a series of novel, highly selective small molecule drugs, and has identified and validated their potential use in a number of target disease indications including thrombosis/cardiovascular, oncology, anti-inflammatory and, in particular, in PAH. The ATXA team has expertise in cardiovascular and cancer biology with technical expertise in platelet biology, cellular and molecular biology, protein biology, pathological and histopathological and immunohistochemical techniques, digital pathology and biostatistics. In addition, ATXA have experience in drug discovery and early development; lead generation; lead optimization; candidate selection; medicinal chemistry; preclinical pharmacokinetics; intellectual property management and commercialization. ATXA Therapeutics Ltd will advance the late-stage development of their novel therapies that display substantial improvements over the existing standard-of-care, addressing critical unmet medical needs for efficacious new therapies to treat PAH.

Stayble Therapeutics AB is a clinical-stage pharmaceutical company based in Gothenburg, Sweden, focused on developing an innovative injection treatment for chronic low back pain caused by degenerative disc changes. The company's primary product, STA363, is an intradiscally injected formulation designed for patients who do not experience relief from conventional treatments such as analgesics and physiotherapy. This minimally invasive treatment aims to address the underlying causes of discogenic pain by stabilizing the disc and preventing the leakage of inflammatory mediators. STA363 is administered as a single injection, with the potential for long-lasting effects and minimal rehabilitation requirements. The experienced multidisciplinary team behind Stayble Therapeutics includes renowned researchers and seasoned professionals from the pharmaceutical industry, all dedicated to alleviating the suffering of millions impacted by chronic back pain.

DART Diagnostics was created with the purpose of improving diagnostics. As scientists, our founders, deal with detection problems on a daily basis. Although more alert to news in their own fields of research the need for better and earlier results is widely spread across water analysis, food safety, and of course clinical diagnostis.

BioBlocks is a collaborative medicinal chemistry research organization focused on drug discovery from initial lead discovery through identification of development candidates. They believe that collaboration empowers scientists to achieve more than any single entity or individual could alone. They join forces with their clients to discover compounds qualified for advancement to phase two clinical trials.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, specializing in the development of diagnostic products and services for liver cancer. Established in 2015, Ophiomics focuses on integrating bioinformatics, artificial intelligence, and genomics to enhance diagnostic and prognostic capabilities in oncology. The company is ISO 13485 and ISO 9001 certified, ensuring adherence to high-quality standards in its operations. Its product pipeline encompasses various stages of development, including pre-clinical programs and those undergoing clinical validation. Ophiomics aims to improve early detection of liver cancer through biomarker-based diagnostic devices that combine molecular signatures with clinical parameters in predictive algorithms, ultimately assisting healthcare providers in treatment selection and clinical follow-up for better patient outcomes.

CytaCoat is developing a new technology of antibacterial coating for medical devices. CytaCoat AB is a private Swedish company located in the Karolinska Institutet Science Park AB in Solna (Stockholm area). The company was founded by a group of researchers from the Karolinska Institute, one of the foremost medical universities in the world, and the Royal Institute of Technology (KTH). It was a special purpose vehicle started with a goal to develop a new technology of antibacterial coating for medical devices. It was based on a discovery that their proprietary polymer surface exhibits a clear effect on several of the most problematic pathogenic bacteria that pose problems in healthcare today. Since then, the company has been focused on transforming this innovation into a fully viable commercial product and make it available through licenses. CytaCoat has a fully equipped laboratory in the Karolinska Institutet Science Park, where both microbiology evaluation, optimisation of the CytaCoat technology and a pilot plant production can be performed. The company has also established contacts with clinical collaborators at Karolinska University Hospital Neonatal Unit and the Division of Clinical Microbiology. CytaCoat has also been cooperating with experienced consultants in regulatory, clinical research organisations, patent experts and providers of specialist analyses.

Inpharmatis offers comprehensive regulatory affairs services to Life Science Industry including Drug Development and Vigilance Services to pharmaceutical, medical device, food supplements, cosmetic and biotech companies. Their area of expertise lies in the European & CIS market. A multi-disciplinary team of qualified regulatory affairs consultants is at your disposal for all aspects of your marketing authorisation applications for active substances and human medicinal products. Inpharmatis shall provide full regulatory support over the whole life cycle of your product.

Biodatup promotes clinical trials using an innovative technology to provide optimal results that match the needs of this demanding sector. Created to revolutionize the management of clinical trials, this unique platform combines the latest advances of engineering in medical information management, with the most innovative techniques of data analysis in health, such as modelling and big data among others.

More than just a medical device, liberDi is an innovative all-in-one portable Digital Dialysis Clinic providing scalable, digital and safe, self-care anywhere. It provides an Intelligent Dialysis Assistant (IDA) and remote medical supervision, together creating the ultimate Digital Dialysis Clinic, allowing patients to choose Anywhere PD (Peritoneal Dialysis) as first modality. liberDi’s system is positioned to replace traditional full-service, in-clinic care with a self-care system suitable for many dialysis patients. Focused on patient care liberation and improved quality of life, liberDi allows many more people requiring dialysis to do so easily and comfortably from wherever they are, be that their home, office or on vacation. Founded in 2014 and supported by a team of world-renowned scientists, engineers and physicians, liberDi’s vision and mission have always been to find a way to free dialysis patients from the need to spend half their lives dialyzing in expensive dialysis clinics and centers. liberDi’s cutting-edge innovation is safe, patient friendly, and portable. In addition to liberating patients, it also enables clinics to optimize their economic model and improve the quality of their service while lowering costs; This creates the optimal, world’s first, 360° platform for Renal patients and caregivers alike.

React4life is an Italian biotech company established in 2016 by Silvia Scaglione and Maurizio Aiello, following over 15 years of research and development. The company focuses on advancing biomedical research through its innovative technology, MIVO® (Multi In Vitro Organ), which represents a next-generation organ-on-a-chip system. This microphysiological platform allows researchers to simulate human biology more accurately in laboratory settings, addressing the limitations of traditional in vitro assays and animal testing. React4life's technology enhances the reliability and predictivity of various applications, including pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals. By enabling the cultivation of three-dimensional human-like tissues for in vitro testing, React4life aims to improve the effectiveness of laboratory experiments and promote ethical research practices.

AXO Science is dedicated to enhancing public health through the development of innovative diagnostic solutions. The company has created a forensic testing tool that offers multi-parameter diagnostic characterizations. This sophisticated tool features an integrated biochip, which incorporates multiple oligonucleotide probes grafted onto a polymer membrane. As a result, forensic departments and diagnostic enterprises can utilize advanced technologies for molecular-based diagnosis, improving their capabilities in the field of diagnostics.

Sedicidodici develops medical devices aimed at measuring the haemorrhagic and thrombogenic potential of patients with cardiovascular diseases and thrombotic-haemorrhagic disorders. Their tools facilitate the monitoring of anticoagulation and antiplatelet drug therapy effects, allowing healthcare providers to assess platelet activation and fibrin formation in blood samples. By predicting thrombotic events, which can lead to strokes and heart attacks, Sedicidodici's devices enhance patient care and improve health outcomes.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Biomode is a Portuguese startup located in Caldas das Taipas that specializes in developing rapid and accurate molecular diagnostic tests for identifying pathogens within the food, environmental, and life sciences sectors. Utilizing Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA-FISH) technology, Biomode's diagnostic kits provide a streamlined approach that eliminates the need for DNA extraction or amplification, ensuring reliability in the presence of inhibitory compounds and focusing solely on viable bacterial cells. The company plans to launch its first product, Probe4Salmonella®, for detecting Salmonella in food samples, followed by additional kits for Listeria monocytogenes and E. coli O157:H7. In the clinical diagnostics realm, Biomode has developed Probe4Pylori®, which is designed for the rapid identification of clarithromycin-resistant Helicobacter pylori strains and is currently seeking investigational device exemption from the FDA to commence field trials. Founded by researchers from the universities of Minho and Porto, Biomode aims to enhance pathogen detection in both food safety and health diagnostics.

AuriGen Medical Limited is an electrophysiology and structural heart company based in Dublin, Ireland, founded in 2016. The company focuses on developing innovative left atrial appendage (LAA) implants designed to address the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). AuriGen's technology targets highly symptomatic patients who are resistant to medication, a demographic that includes over 3 million individuals in the United States and Europe. The rising incidence of AF, particularly among aging populations, underscores the urgent need for effective treatment alternatives. AuriGen's devices incorporate custom LAA occluder implants and are designed to enhance patient outcomes by reducing reliance on anticoagulants and anti-arrhythmic medications. With the annual costs of managing medication-resistant AF running into billions, AuriGen aims to provide cost-effective solutions that improve treatment efficacy and patient quality of life.

SunRegen is a biopharmaceutical company with a mission to develop drugs to treat neurodegenerative diseases. They focus on innovative treatments for patients suffering from neurological, neuromuscular and ophthalmic diseases. Their first product candidates in development target primary optical atrophy. They are further evaluating them for use in serious neurological / neuromuscular diseases such as ALS, Huntington's, Alzheimer’s and Parkinson’s disease. Their team is composed of passionate and innovative founders and experts who have solid track records in drug development and clinical research in multinational pharmaceutical companies or management experience in international technology enterprises. Their determination in bringing life-changing treatments to patients encompasses everything they do.

Z.M.D. Medical develops and commercializes a therapeutic remedy to cure cancer of all types using the immune system. Z.M.D has set a goal to produce probiotic preparations to rehabilitate distressed colon microflora in order to eliminate cancer from patients’ immune systems and help it recover. Probiotic is designed to eliminate cancerous conditions in patients. This project is also based on the onco-lytic activity of bacterial flora of human intestines. When a patient suffers from low onco-lytic activity, the bacteria must be replaced with the same bacteria with high onco-lytic activity taken from a healthy donor. This idea was tested in animal experiments and is currently being prepared for clinical trials.

Glucostratus Ltd develops innovative solutions for remote monitoring of blood glucose levels, primarily targeting patients with diabetes and healthcare professionals. Founded in 2005 and based in Helsinki, Finland, the company provides a cloud-based platform that captures blood glucose data via mobile technology, enabling patients to share their results with healthcare providers. This system allows professionals to set personalized targets and receive automated alerts regarding any deviations, facilitating effective remote monitoring of insulin treatment. Additionally, Glucostratus offers a digital solution for diagnostic testing and generates comprehensive reports in accordance with treatment guidelines. Their services include a user-friendly IoT solution designed for elderly diabetics, ensuring accessibility for those with limited technological skills and addressing the growing needs of the home care sector.

PharmaBiome is specialized in the isolation, characterization, and technology of novel intestinal microbes. Their technology platform optimizes the lean and efficient development and production of defined, function-based microbiome therapies to treat intestinal diseases. PharmaBiome’s proprietary development pipeline allows a fast translation from the identification of mode of action to a product ready for clinics, using tailored, ecologically sound bacterial mixtures.

Lyme Diagnostics offers reliable, standard diagnostic system for diagnosing Lyme borreliosis. Lyme diagnostics is primarily focused on the more exact, routine diagnostics of Lyme disease, building on the innovative technologies developed by the diagnostic & therapeutic workgroup of the Lyme Borreliosis Foundation. We offer the results of 30 years of work by 8 medical professionals. Currently, our novel diagnostic methods are supplemented with laboratory-standard, widely-accepted diagnostic procedures, and carefully confirmed by clinical diagnosis. The company's objective is that - after clinical testing - we will be able to offer one single screening method across Europe, and in North America.

HAWK Biosystems specializes in cancer diagnostics through a companion diagnostics platform that identifies post-translational modifications and protein-protein interactions in pathology samples. The platform quantifies these interactions in single-cell and fixed tissue samples, maintaining the integrity and heterogeneity of the tissue. This technology offers medical practitioners and pharmaceutical companies a novel approach to treatment decisions, particularly in cancer, inflammation, and immune disorders. HAWK Biosystems aims to enhance precision medicine by enabling targeted therapies that match patients with the treatments most likely to be effective, thereby improving patient outcomes, quality of life, and reducing overall drug costs. The company seeks to establish collaborative opportunities within the European health system to further its impact in the field.

Glycobond specializes in the development and production of proprietary carbohydrate-binding reagents aimed at enhancing diagnostics for liver diseases and cancer. The company has created HepaCheC™, an ELISA-based assay that identifies abnormal and cancer-specific glycosylation on alpha-1 acid glycoprotein (AGP), an acute phase plasma protein primarily produced in the liver. This innovative assay allows for analysis using simple blood samples, leveraging a patented fucose-binding protein known as Mono-F. Glycobond's approach has demonstrated promising results in monitoring patients at risk of developing hepatocellular carcinoma (HCC), offering a valuable tool for physicians in diagnosing and managing liver conditions.

Ilya Pharma is a pharmaceutical company focused on developing next-generation biological drugs aimed at enhancing wound healing in skin and mucosa. Founded in 2016 as a spin-out from Uppsala University and the Swedish University of Agriculture, the company employs a unique technique that genetically modifies lactic acid bacteria, commonly found in yogurt. These engineered bacteria serve as vectors to produce and deliver healing substances directly to wounds or within the gastrointestinal tract. This innovative approach is designed to provide accelerated healing for patients, particularly those with diabetes, while maintaining cost-effectiveness.

Sana Health, Inc. is a digital health company specializing in a bio-therapeutic device aimed at fostering relaxation to alleviate pain and tension. The company has developed a non-addictive mask and headphone system that employs audio-visual stimulation to enhance the balance between the brain's left and right hemispheres, facilitating a deep state of meditation. This innovative device uses coordinated pulses of light and sound to guide users into a restorative state, thereby improving mental well-being and addressing chronic pain and insomnia. In addition to the hardware, Sana Health offers a mobile application available on both the App Store and Google Play, allowing users to access its features conveniently. Founded in 2015 and headquartered in Lafayette, Colorado, with an additional office in Mill Valley, California, Sana Health is involved in pivotal studies concerning its technology's applications for conditions such as fibromyalgia and neuropathic pain, as well as trials focusing on anxiety and PTSD.

Ikan Biotech SL, based in Noáin, Spain, specializes in the development of innovative enzybiotics and preclinical services utilizing zebrafish models. Founded in 2015, the company provides a unique platform that allows for the creation of tumor models, enabling the healthcare industry to design and assess the efficacy of potential cancer treatments. Ikan Biotech's zebrafish models facilitate the microinjection of tumor cells, which helps researchers evaluate the safety and identify potential adverse effects of drug candidates during the early stages of development. The company's services cater to a variety of sectors, including pharmaceuticals, biotechnology, environmental science, and nutraceuticals, among others.

Eversens is a company focused on the design, development, and manufacturing of non-invasive clinical diagnostic systems that detect exhaled biomarkers. Its technology aims to facilitate the diagnosis and monitoring of various diseases, providing patients with reliable and painless diagnostic options. By enhancing the accuracy of exhaled biomarker detection, Eversens seeks to improve individuals' health and quality of life while promoting a sustainable healthcare system.

CORNEA_project is a company dedicated to the research, development and commercialization of solutions and treatments to corneal eye diseases. The cornea is the first surface of the eye, with the highest dioptric power of the ocular optical system, and is of vital importance to see good quality images. Small variations in the corneal surface produces large changes in the quality of patients' vision. Their goal is to ensure the corneal integrity, develop and deliver the best possible treatments for the researched pathologies, and improve the quality of life of patients.

Regulaxis is focused in research, development and licensing of human innovative synthetic molecules for high unmet medical needs

Castor is an international health-tech company founded by CEO Derk Arts, MD, Ph.D. Their cloud-based clinical data platform simplifies the entire clinical trial process, from recruitment to analysis, for researchers worldwide. More than 50,000 researchers across 90 countries are using Castor to supercharge their research. Castor’s platform has supported more than 4,000 commercial and academic studies that cover a broad range of therapeutic areas including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Researchers on the platform generate vast amounts of data from traditional and remote trials, and Castor recently reached milestones of 180,000,000 data points and 2,000,000 enrolled patients. Castor’s goal is to make the world’s research data reusable, enabling AI-driven clinical trials, and ultimately creating a future in which they maximize the impact of data through reuse.

SenzaGen AB is a biotechnology company based in Lund, Sweden, specializing in in vitro genomic allergen rapid detection (GARD) sensitization tests. Founded in 2010 as a spin-out from Lund University, SenzaGen provides animal-free testing solutions for the cosmetic, pharmaceutical, and chemical industries, focusing on immunotoxicological assays. Its proprietary product line includes GARDskin, which predicts chemical sensitization, GARDpotency, which classifies sensitizers based on genomic biomarkers, and GARDair, an assay for respiratory sensitizers. The company operates through its own laboratory and collaborates with licensed contract research organizations to deliver its services. SenzaGen also engages in partnerships, such as its collaboration with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company serves multiple market segments, including cosmetics, chemicals, medical devices, pharmaceuticals, and food additives, with a significant portion of its business derived from the pharmaceutical sector.

BRI.Tech is breaking new ground in orthopedic and trauma surgery by making a second surgical intervention unnecessary with biodegradable magnesium. The main idea behind BRI.Tech is all about the treatment of broken bones in children. In dealing with fractures, the use of a stabilizing implant is often unavoidable – and then, after a period of approximately six weeks, when bone healing is in a final state, a second operation is necessary to remove the implant from the growing skeleton. This, obviously, always constitutes a risk and might require another unpleasant hospital stay. Thus, developing a stable implant that dissolves naturally as soon as the bone is able to take over the load again is a major step towards avoiding pain and discomfort. BRI.Tech’s intention is to avoid surgical interventions for implant removal, which helps to reduce costs for the European healthcare system. BRI.Screw is the result of eight years of preclinical research, combined with state-of-the-art materials. BRI.Screw is there to stabilize a fractured bone as long as it is needed in order to support it. Unlike conventional implants, its material dissolves naturally and is excreted by the body as soon as the bone is fully functional again. BRI.Tech was founded in 2016 and is a start-up company located in Graz, Austria.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory disorders by enhancing epithelial barrier integrity. This barrier is crucial for the proper functioning of human skin, lung tissue, the intestinal tract, and genitalia. Disruption of this barrier is linked to chronic inflammation and various diseases. The company is creating a proprietary portfolio of orally available macrolide drug candidates, which aim to serve as first-in-class disease-modifying therapeutics for chronic respiratory conditions and other significant unmet medical needs. EpiEndo's lead candidate, EP395, is designed to be the first oral, non-antibiotic macrolide that strengthens barriers and reduces inflammation in patients with chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases.

Ectin Research AB is a pharmaceutical company focused on developing a novel treatment for cancer, specifically targeting metastatic bladder cancer. The company's lead drug candidate, MFA-370, is a combination therapy that includes a medication originally used for a tropical disease, which unexpectedly demonstrated the ability to eliminate cancer tumors. Research indicates that MFA-370 may enhance anti-cancer effects across a variety of cancer cell lines, potentially benefiting over 40% of all cancer types. Ectin Research aims to prove the efficacy of this treatment in bladder cancer before exploring its applications in other cancers, such as breast, colorectal, and prostate cancer. The chosen pharmaceuticals for MFA-370 are well-established and associated with limited or no side effects, which the company believes will streamline the developmental process for this promising therapy.

Cercare Medical is a Danish company that specializes in medical imaging technology aimed at improving acute stroke management. Established in 2013, originally under the name Combat Stroke, the company has developed a software tool that assists clinicians in evaluating the effects of strokes. This innovative technology allows for rapid analysis, generating infarct area and perfusion area assessments within 30 seconds while utilizing artificial intelligence to identify and quantify stroke lesions. By providing advanced perfusion analysis, Cercare Medical enables healthcare professionals to deliver personalized care, ultimately enhancing patient outcomes in stroke and cardiac failure cases.

Betalin Therapeutics is a privately-held company. We develop a cell therapy solution for insulin-dependent diabetes, an Engineered Micro-Pancreas (EMP). The EMP is a combination of harvested pancreatic islets (also known as Islets of Langerhans) and a proprietary biological micro-environment for supporting the harvested cells. After promising in-vitro results and preliminary in-vivo results, Betalin Therapeutics is currently putting efforts to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials.

M.M.A. Tech Ltd. operates as a technology company for biomaterial applications for medical implants and devices in the fields of cardiology, dental, and orthopedic. It engages in the implementation of biocompatible wear-resistant polymers for bone implants and coatings or bulk orthopedic implants. The company’s products also include dental implants and spine spacers. Its end users include companies producing orthopedic implants, private doctors and medical facilities, hospitals and surgical facilities, and veterinary companies. M.M.A. Tech Ltd. has developed an Acetabular liner for hip replacement arthroplasty procedures made of Polyimide MP1™ to overcome the life span problems often encountered by total arthroplasty hip surgery patients. Common complications are bone resorption and a shifting of the implant from its original position due to wear and debris from the polyethylene in use today. The MP1™ Acetabular liner has received CE approval and M.M.A. Tech Ltd is ISO 13485 certified since October 2011. M.M.A. Tech Ltd. is conducting a 3rd clinical study of 100 patients in New Zealand. M.M.A. Tech Ltd established a contract with a leading orthopedic company in Europe. M.M.A. Tech Ltd. is initiating a new clinical study of 15 patients in Israel, which is already registered in ClinicalTrials.gov (NIH no. NCT02503891). The results of the clinical study will serve as a pilot for the FDA approval. M.M.A. Tech Ltd. submitted a Master File of MP1™ for the FDA which was accepted under the No. MAF 2543 on October 2014. M.M.A. Tech has developed an Acetabular liner for hip replacement arthroplasty procedures made of Polyimide MP1™ to overcome the life span problems often encountered by total arthroplasty hip surgery patients. Common complications are bone resorption and a shifting of the implant from its original position due to wear and debris from the polyethylene in use today.

Respinor is a medtech company focused on developing innovative respiratory medical technologies. The company has created a non-invasive ultrasound device known as DiaMon, which is designed for continuous monitoring of diaphragm function, the primary muscle involved in breathing. This technology offers precise, real-time information about diaphragm performance, making it particularly beneficial for critically ill patients in intensive care settings. By providing an objective measure of breathing, Respinor aims to enhance the quality of care delivered by healthcare professionals while also helping to reduce associated costs. The company is working towards clinical validation and commercialization of its ultrasound technology, capitalizing on a significant market opportunity within critical care and respiratory medicine.

Curtana Pharmaceuticals was founded on a mission to develop the first truly targeted therapies for the treatment of the most aggressive types of brain cancer. The company’s drug development program is based on the pioneering research of Dr. Santosh Kesari, who is currently the Chairman of the Department of Translational Neuro-oncology and Neuro-therapeutics at the John Wayne Cancer Institute. Curtana’s senior leadership brings years of experience in the pharmaceutical industry, with extensive backgrounds in the development of new molecular entities for the treatment of cancer as well as CNS disorders. Curtana initiated operations in San Diego, California in 2013. Following the award of a highly prestigious and competitive grant ($7.6M) from the Cancer Prevention and Research Institute of Texas (CPRIT) in August 2014, the company relocated its lab and offices to Austin, Texas. Current investors include Thynk Capital, angelMD, Biosense Global, DEFTA Partners, and other anonymous investors.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.

Inovotion is a contract research laboratory specializing in the evaluation of anticancer drug efficacy and toxicity. The company employs a distinctive approach to in vivo testing, which is crucial for the discovery and development of oncology and immuno-oncology treatments. Inovotion's technology supports preclinical drug development by monitoring the growth and spread of human tumor cells, allowing researchers from both industry and academia to validate therapeutic targets effectively. By providing cost-effective in vivo evaluations, Inovotion enables chemists and biologists to advance their drug discovery programs efficiently.

World leader in the field of telomeres, Life Length offers a series of tests to measure cellular senescence, a crucial biological marker to establish biological age, for the early detection of chronic diseases and for risk stratification. Life Length is the only company in the world capable of measuring telomeres individually at a chromosomal level using its Telomere Analysis Technology® (TAT®). The company offers its testing services to relevant industries such the pharmaceutical for R & D and to carry out clinical studies, and also to doctors working in preventive medicine and personalized patient care in fields such as cardiology or oncology where telomeres have shown to make a significant contribution to the development of the disease. Life Length is accredited by the US Federal Government through CLIA as a clinical laboratory, it also holds the prestigious IS0 15189 accreditation and its ONCOCHECK project has received funds from the EU ‘Horizon 2020’ program under the financial agreement number 738707.

Decodeon empowers people to cure their own disease by offering personal insights and enabling them to be part of medical research. Currently, 80% of all clinical trials are delayed or cancelled. By finding and connecting matching participants to clinical trials, the company help to speed up the development of medicine. Its goal is to advance knowledge and ultimately help people with a rare disease to lead better lives.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Lipum is a clinical-stage biopharmaceutical company focused on developing innovative treatments for chronic inflammatory diseases. Its lead candidate, SOL-116, is a humanized antibody designed to target a previously overlooked molecule in the immune system, offering a novel mechanism of action that may reduce adverse effects compared to existing therapies. The primary focus of Lipum's research is on Rheumatoid Arthritis, a debilitating autoimmune disease that significantly impacts patients' quality of life. Additionally, Lipum is investigating the treatment of Juvenile Idiopathic Arthritis, which could qualify for orphan drug designation due to its rarity in children. The company is also exploring potential applications for other chronic inflammatory conditions, including Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis, addressing a significant unmet medical need in these areas.

GlycoMar Limited is a biotechnology company focused on discovering and developing innovative products for the human healthcare and personal care markets. Founded in 2005 and based in Oban, United Kingdom, GlycoMar specializes in addressing unmet clinical needs related to inflammatory diseases such as eczema, psoriasis, asthma, and inflammatory bowel disease through the development of consumer healthcare products and novel pharmaceuticals. The company also creates glycomolecule products for the cosmetic and nutraceutical sectors. In addition to product development, GlycoMar offers a comprehensive range of carbohydrate research and development services, from initial discovery to pilot-scale processing. The company collaborates with MicroA AS in a joint venture to manufacture cosmetic ingredient products. GlycoMar's efforts are rooted in the exploration of marine organisms, enabling it to evaluate and commercialize unique biological products that serve the pharmaceutical, consumer healthcare, cosmetic, and nutraceutical markets.

Viomedo is Germany's largest online platform for clinical trials, aimed at connecting patients with medical research to enhance existing therapies and discover new cures. The platform features a user-friendly search engine that allows patients, research institutions, life sciences companies, and contract research organizations (CROs) to easily find and participate in ongoing clinical trials. By collaborating with researchers, patient support groups, research hospitals, and pharmaceutical companies, Viomedo seeks to transform the landscape of medical research across Europe. The company's mission is to provide patients with access to cutting-edge treatments and contribute to the advancement of healthcare.

Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiovascular diseases and on certain cancers. Their lead AMPK activator compound O304 is currently in Phase IIa clinical trial.

Clinical Laserthermia Systems AB is a Swedish company focused on developing and marketing innovative therapies and instruments for the thermal treatment of solid tumors, particularly cancer. The company offers the TRANBERG Thermal Therapy System, which features a laser unit with advanced monitoring capabilities and is designed for heat-induced immunotherapy, specifically the imILT treatment. Its product range includes disposable materials and applicator kits used in image-guided laser ablation. Clinical Laserthermia Systems is also engaged in the development of treatments for various types of cancer, including breast, pancreatic, skin, and prostate cancers. Collaborations with organizations such as Image Guided Therapy SA and MRI Interventions, Inc. aim to enhance the capabilities of their technologies, including software for MR-generated temperature monitoring and navigation for laser ablation in spine and neurosurgery. The company is headquartered in Lund, Sweden, with additional subsidiaries in Berlin and Boston.

Ikan Biotech SL, based in Noáin, Spain, specializes in the development of innovative enzybiotics and preclinical services utilizing zebrafish models. Founded in 2015, the company provides a unique platform that allows for the creation of tumor models, enabling the healthcare industry to design and assess the efficacy of potential cancer treatments. Ikan Biotech's zebrafish models facilitate the microinjection of tumor cells, which helps researchers evaluate the safety and identify potential adverse effects of drug candidates during the early stages of development. The company's services cater to a variety of sectors, including pharmaceuticals, biotechnology, environmental science, and nutraceuticals, among others.

PolTREG is a biotechnology company focused on developing innovative therapies using T-regulatory cells (TREGs) for the treatment of autoimmune diseases, notably type 1 diabetes and multiple sclerosis. Established as a spin-off from the Medical University of Gdańsk, the company aims to commercialize its patented TREG method, which has shown promising results in clinical trials. PolTREG's portfolio includes four advanced projects currently in clinical development, backed by a team of experienced managers, biotechnology specialists, and scientists. The founders bring over 17 years of expertise in T-regulatory cell applications for autoimmune therapies. The company's Scientific Advisory Board comprises leading experts in the field, ensuring a strong foundation for research and development. PolTREG is uniquely positioned as the sole entity authorized to implement its research findings and utilize its growth method for clinical applications, with a commitment to delivering its breakthrough therapies to patients.

Abich is a contract research organization (CRO) specializing in research and analysis services for manufacturers in the cosmetics, medical devices, and consumer products sectors. With over a decade of experience, Abich has established a clinical division focused on safety, tolerability, and efficacy testing on healthy volunteers. The company houses advanced biological cell laboratories capable of performing in vitro safety tests that adhere to OECD methods, utilizing specific cell lines and reconstructed human tissues. Additionally, Abich offers a variety of efficacy tests to support the development of cosmetic products, drugs, medical devices, flavorings, supplements, foods, and detergents. Its analytical chemistry sector employs advanced techniques such as HPLC, Ultra-HPLC, GC-MS, and ICP-OES for quality control of raw materials and finished products. The microbiology laboratory conducts comprehensive analyses, including the identification of microorganisms and various challenge tests. Abich's team, composed of biologists, chemists, biotechnologists, and biomedical engineers, collaborates with clients to create tailored study protocols and analytical methods.

Oncovision (GEM Imaging S.A.) is a Spanish technologic start-up company created in 2003 with the initiative of the Corpuscular Physics Institute (CSIC) and the University of Valencia. They work in Molecular Vision applied to Health Sciences focusing in: cancer diagnosis and treatment, and advanced research in neurology, oncology, and cardiology. They are a company focused on Molecular Vision, which creates, develops and markets new medical technologies, global innovations with relevant clinical and economic advantages, often representing a breakthrough in current standards of diagnosis and treatment. ONCOVISION´s original, fresh technology, strong intellectual property, top-level clinical evidence, leading global reference centers, and pioneering protocols, is supported by its dynamic cross-functional team. ONCOVISION is opening unprecedented options in the treatment of cancer and serious cardiac and neurological diseases. Their team and the company’s technologies have been recognized by Spanish and European prestigious institutions. In 2007, the company was selected as one of the “20 Best Technologic Companies in Spain” and won the “National Medical Physics 2007 Congress Award” In 2008, it was one of the “20 Best Health Technology Companies in Europe” by the prestigious European Technology Tour, as well as finalist in the “National 25th Aniversary Enisa Award” Prof. Jose María Benlloch, active member of the company, won in 2008, the well-known “Jaime I” award. Scientists, technicians, and technologists of ONCOVISION have dozens of publications and presentations at scientific and medical conferences worldwide. Their shareholding, based in Valencia, was strengthened in August 2006 by the Spanish venture capital firm Bullnet, unifying its proven track in technological and management capabilities with companies in Spain and Portugal. The company is managed by a multi-task professional team with international experience. With proven clinical and scientific results, differentiated technology with enormous potential for future technological and financial capacity, intellectual property and developing lines, ONCOVISION is today ahead in the Spanish and European Health Industry.

Access for Life provides solutions for chronic disease patients, adults and pediatrics, who require repetitive vascular access in hemodialysis, chemotherapy, blood disorders, and digestive disorders. These disease patients frequently require repetitive vein wall puncturing to implement therapy. The JEM series of smart devices are inserted subcutaneously to the outside of a vein, fistula or graft, just beneath the skin. Their design and technology ensure repetitive vessel puncturing in the exact same spot. JEM’s attachment and internal design will prevent hematomas, thromboses and stenosis. JEM is projected to reduce the rate of clinical complications and reduce patient morbidity and mortality by providing safer venous access, while lowering healthcare costs. Particularly in dialysis patients who require repetitive access to fistulas where damage from pseudoaneurysms and hematomas may lead to increased morbidity and mortality. Access for Life's JEM patented chamber, affixed to the vessel wall, will avoid these complications and in cancer patients, its placement on an upper arm vein avoids chest wall complications. It's suitable for all vascular access patients.

Icosagen Group is a contract research provider and technology developer based in Tartumaa, Estonia, serving the biopharmaceutical and biotechnology sectors, as well as academic institutions. The company specializes in high-end biotechnology services, including protein and antibody production, as well as virus-like particle (VLP) production. Its product offerings encompass antibodies, proteins, ELISA kits, transfection reagents, and DNA/RNA isolation tools. Additionally, Icosagen provides quality control services, such as food microbiology testing and allergen testing. The company is involved in various international and national research initiatives, contributing to projects like INTENSO, MAARS, and EURIPRED. Icosagen's proprietary QMCF Technology allows for the stable expression of recombinant proteins and antibodies in mammalian cells, facilitating the development of cell-based assays for screening purposes. The Icosagen Group comprises three entities: the parent company Icosagen AS and its subsidiaries, Icosagen Cell Factory Ltd and IcoPark Ltd.

Oncolinx is engaged in the development of advanced targeted cancer therapies known as antibody-drug conjugates (ADCs), in collaboration with the National Cancer Institute. These ADCs utilize a patented immune-activating drug payload called Azonafide, which is specifically designed to target cancer cells while sparing healthy cells, thus minimizing the side effects commonly associated with traditional chemotherapy. The company is partnered with over 14 leading pharmaceutical companies and 6 academic laboratories worldwide, working on ADCs for 30 different cancer indications. This innovative approach not only aims to induce cancer cell death but also to stimulate the immune system, offering a potentially less painful alternative to conventional treatments. Oncolinx plans to initiate clinical trials for one of its partnered programs.

Optellum develops an imaging biomarker for smart lung cancer detection. Optellum’s vision is to redefine cancer care, by enabling every clinician, in every hospital, to manage their patients in the optimal way. They do that by providing end-end IT platform for personalized early diagnosis and therapy, based on the collective experience of thousands of doctors pooled by machine learning applied to vast patient datasets. Their first suite of products targets management of patients at high risk of developing lung cancer – the world’s deadliest and commonest cancer – from early diagnosis through to treatment. Optellum comprises a team of award-winning medical imaging software, AI, and clinical experts who met at Oxford’s world-renowned computer vision lab. Between us, they have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. They are backed by an Advisory Board comprising world-leading clinicians and experts in deep learning ; and Oxford's most prominent investors. They are building up their product development team – join their fight against cancer, working together with former software engineers from top technology companies (Amazon, Facebook, Redhat) and veterans of medical imaging startups (e.g. Mirada Solutions – acquired by Siemens).

Lyme Diagnostics offers reliable, standard diagnostic system for diagnosing Lyme borreliosis. Lyme diagnostics is primarily focused on the more exact, routine diagnostics of Lyme disease, building on the innovative technologies developed by the diagnostic & therapeutic workgroup of the Lyme Borreliosis Foundation. We offer the results of 30 years of work by 8 medical professionals. Currently, our novel diagnostic methods are supplemented with laboratory-standard, widely-accepted diagnostic procedures, and carefully confirmed by clinical diagnosis. The company's objective is that - after clinical testing - we will be able to offer one single screening method across Europe, and in North America.

Px HealthCare focuses on enhancing patient outcomes in oncology through its innovative platform, OWise. This platform offers evidence-based mobile and web applications specifically designed for individuals diagnosed with breast or prostate cancer. OWise supports patients by providing personalized digital tools that facilitate real-time health data sharing with care teams and help bridge the evidence gap through patient-centric insights. As cancer care costs surpass $1.16 trillion annually, Px HealthCare aims to alleviate both individual and financial burdens by improving patient well-being and clinical results while reducing healthcare expenses. The OWise breast cancer app has received independent validation, garnering recommendations from 90% of patients and clinicians. Recognized for its excellence, OWise was selected by the NHS Innovation Accelerator and has received numerous awards. Additionally, Px HealthCare leverages advanced data analytics on anonymized patient-reported outcome data to offer valuable insights that contribute to better cancer treatment effectiveness and cost-efficiency on a global scale.

Inbiomotion is dedicated to the development and commercialization of a biomarker that predicts metastasis, with the aim of enhancing the quality of life for breast cancer patients through personalized adjuvant treatment. Established in 2010 as a spin-off from IRB Barcelona and ICREA, the company has created a diagnostic assay based on a highly selective single-gene biomarker. This biomarker has shown promise in identifying early-stage breast cancer patients who are likely to benefit from bisphosphonate adjuvant treatment, potentially improving their overall survival and reducing the risk of invasive disease. Additionally, the biomarker can predict the likelihood of metastases relapse from primary tumors at an early stage, positioning Inbiomotion to advance clinical practices in personalized medicine for breast cancer care.

Vitalograph is a prominent manufacturer of respiratory diagnostic devices, specializing in spirometers and other equipment for the management of respiratory conditions. With over 50 years of experience, the company provides a diverse range of products and services that cater to clinical trials, primary care, occupational health, sports medicine, asthma management, emergency services, and hospitals. Vitalograph's reputation in spirometry is well-established globally. In addition to its core offerings, the company has recently expanded its product line to include innovative solutions for capturing cardiac data, suitable for both home and clinical settings. Their commitment to quality ensures that healthcare professionals have access to precise and intuitive devices for effective respiratory care.

Psyomics is engaged in the development of proteomic diagnostics aimed at improving the early diagnosis and treatment outcomes for individuals with neuropsychiatric disorders. The company offers a web-based assessment triage system that integrates digital profiling with advancements in biological research to enhance diagnostic accuracy. This approach assists primary care practitioners in effectively managing their patients' mental health needs by replicating a psychiatric assessment at the initial point of contact. By doing so, Psyomics facilitates improved recovery outcomes for patients suffering from mental health disorders.

Finesse Medical Ltd is a company that designs and manufactures a diverse range of wound and skin care products aimed at managing various skin conditions. Established in 2004 and based in Longford, Ireland, the company specializes in advanced technologies such as polyurethane foam, hydrocolloids, skin barrier films, and silicone foam dressings. In addition to its product offerings, which include moisturizers, incontinence care, and specialized treatments for conditions like psoriasis and eczema, Finesse Medical provides comprehensive outsourcing solutions in contract manufacturing. These services encompass tube filling, bottle filling, RF welding, die cutting, packaging, and sterilization. The company also supports product development through material sourcing, biocompatibility testing, and clinical reporting. Overall, Finesse Medical combines innovation in healthcare product development with efficient manufacturing capabilities to address the needs of the wound care and skin treatment markets.